Trinity developed a strategy to drive differentiation of a biosimilar through service offerings and contracting in Canada, and select LatAm and MEA countries.
The client wanted to identify the service offerings and contracting that can drive differentiation and preference of a biosimilar versus the originator biologic and other biosimilars.
Trinity conducted an internal working session with the local and regional team to vet hypotheses, followed by a semi-qual / quant primary research program moderated in local language with n=185 stakeholders, including key opinion leaders (KOLs), physicians, nurses, hospital administrators and payers.
- Catalogue of value-added services and contracts offered by the originator biologic across market segments
- Biosimilar defense strategies implemented by the manufacturer of the originator biologic
- Stakeholder influence map outlining formal and informal leverage points to drive biosimilar uptake
- Service offering and contracting expectations for biosimilars and impact on biosimilar differentiation
- Strategic recommendations to drive differentiation of a biosimilar
Project Outcomes & Impact
Trinity was able to support the client with driving differentiation of a biosimilar through service offerings and contracting, with strategies tailored to market segment.
Sign up for the latest intelligence